International urogynecology journal and pelvic floor dysfunction · 2009
Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Altman Daniel, Granath Fredrik, Mattiasson Anders, Falconer Christian
Аннотация
INTRODUCTION AND HYPOTHESIS: Nationwide use and costs of anticholinergic drug for overactive bladder are unknown.
METHODS: We performed a nationwide study based on the Swedish Register on Prescribed Pharmaceuticals.
RESULTS: From 2000 to 2007, there was a 68.8% increase in dispensed anticholinergic drugs in a population of 9 million. More than 93 million DDDs (calculated average maintenance dose per day) of anticholinergic drugs were dispensed corresponding to an overall DDD/TID (DDD per 1,000 inhabitants per day) of 3.5 per 1,000 persons per year. Approximately two thirds of anticholinergic drugs were prescribed to women, regardless of drug type. In 2007, the cost for anticholinergic drugs was 22 million <euro> of which tolterodine comprised 70.8%. Solifenacin and darifenacin steadily increased their DDD/TIDs after market introduction.
CONCLUSIONS: In this nationwide study, there was a 70% increased rate of expedited prescriptions of anticholinergic drugs for the treatment of overactive bladder in a relatively stable population.
METHODS: We performed a nationwide study based on the Swedish Register on Prescribed Pharmaceuticals.
RESULTS: From 2000 to 2007, there was a 68.8% increase in dispensed anticholinergic drugs in a population of 9 million. More than 93 million DDDs (calculated average maintenance dose per day) of anticholinergic drugs were dispensed corresponding to an overall DDD/TID (DDD per 1,000 inhabitants per day) of 3.5 per 1,000 persons per year. Approximately two thirds of anticholinergic drugs were prescribed to women, regardless of drug type. In 2007, the cost for anticholinergic drugs was 22 million <euro> of which tolterodine comprised 70.8%. Solifenacin and darifenacin steadily increased their DDD/TIDs after market introduction.
CONCLUSIONS: In this nationwide study, there was a 70% increased rate of expedited prescriptions of anticholinergic drugs for the treatment of overactive bladder in a relatively stable population.
Предметные рубрики MeSH
Benzhydryl CompoundsBenzofuransCholinergic AntagonistsCresolsFemaleHealth Care CostsHumansMuscarinic AntagonistsPharmacoepidemiologyPhenylpropanolaminePyrrolidinesQuinuclidinesRegistriesRetrospective StudiesSolifenacin SuccinateSwedenTetrahydroisoquinolinesTolterodine TartrateUrinary Bladder, Overactive